Lebrikizumab
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Lebrikizumab: From Atopic Dermatitis to Severe Nonproliferative Diabetic Retinopathy
One-Sentence Summary
Lebrikizumab is an anti-IL-13 monoclonal antibody marketed in the US as EBGLYSS, used for moderate-to-severe atopic dermatitis. The TxGNN model predicts it may be effective for severe nonproliferative diabetic retinopathy, but there are 0 clinical trials and 0 publications supporting this direction, so it is a model prediction only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Moderate-to-severe atopic dermatitis (the license records have no indication text, so this comes from the pack’s mechanistic notes) |
| Predicted New Indication | Severe nonproliferative diabetic retinopathy |
| TxGNN Prediction Score | 97.94% |
| Evidence Level | L5 |
| US Market Status | ✓ Marketed |
| Number of NDAs | 2 records (both BLA761306) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the DrugBank field. Lebrikizumab is a high-affinity antibody that binds IL-13. It blocks IL-4Rα/IL-13Rα1 heterodimer signaling, a core pathway in type 2 inflammation.
This link is weak. Diabetic retinopathy is driven mainly by VEGF, hyperglycemia-induced vascular injury, and inflammation. IL-13 is not a recognized driver, and no known mechanism connects IL-13 blockade to retinal microvascular disease. The high TxGNN score reflects a graph-based association only.
Two further points limit the prediction:
- Route: Lebrikizumab is a subcutaneous injection. Route compatibility with a retinal indication has not been assessed.
- Same-disease prediction: The plain “diabetic retinopathy” prediction (rank 3) has no trials or publications either.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| BLA761306 | EBGLYSS (Eli Lilly and Company) | Injection, solution | Not listed in the record |
The record appears twice with identical content.
Safety Considerations
Please refer to the package insert for safety information. No drug interactions were found in the queried data.
Other Predicted Indications (for context)
| Predicted Indication | Evidence Level | Decision | Note |
|---|---|---|---|
| Dermatitis | L1 | Proceed with Guardrails | Label confirmation, not new repurposing. Phase 3 RCTs (ADvocate1/2, ADhere) and long-term data exist for atopic dermatitis only. Do not extend to other dermatitis subtypes without separate evidence. |
| Psoriasis | L4 | Hold | Retrieved trials and papers concern atopic dermatitis, matched by keyword only. A 2026 case report describes lebrikizumab-induced psoriasis. |
| Drug-induced osteoporosis, HER2-positive breast carcinoma, and 5 others | L5 | Hold | Graph prediction only, no supporting studies. |
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked prediction, severe nonproliferative diabetic retinopathy, has only a model score. It has no trials, no literature, and no plausible IL-13 mechanism. Diabetic retinopathy is a VEGF- and vascular-driven disease.
To proceed, the following is needed:
- Preclinical or mechanistic evidence linking IL-13 signaling to diabetic retinopathy
- Detailed mechanism of action data from DrugBank
- Package insert warnings and contraindications (blocking data gap DG001)
- Route and ocular safety assessment for a retinal indication
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.